Literature DB >> 25275022

Differential expression of VEGF and IL-1alpha after photodynamic treatment in combination with doxorubicin or taxotere.

Daiva Dabkeviciene1, Ausra Sasnauskiene1, Eva Leman2, Raimonda Kvietkauskaite1, Vida Kirveliene3.   

Abstract

AIM: To show the impact of chemotherapeutic drugs doxorubicin and taxotere on the molecular pattern of cell response to photodynamic treatment (PDT).
MATERIALS AND METHODS: Human squamous cell carcinoma cells A-431 were studied. Apoptosis was investigated by recording caspase-3 activity. Expression of IL-1alpha and VEGF on mRNA and protein levels was measured by qPCR and ELISA.
RESULTS: PDT in combination with either doxorubicin or taxotere was found to be more cytotoxic in comparison to either single-treatment. The expression of IL-1alpha and VEGF was up-regulated in PDT-treated cells, either alone or in combination with doxorubicin or taxotere. Addition of doxorubicin to the cytokine induction after PDT was not detected, however, taxotere promoted significant over-expression of IL-1alpha and VEGF on the protein level.
CONCLUSION: Contribution of chemotherapeutic drugs to IL-1 alpha and VEGF release from cells which received dual treatment involving PDT could be significantly different, despite the same level of cytotoxicity. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  IL-1alpha; Photodynamic therapy; VEGF; doxorubicin; mTHPC; taxotere

Mesh:

Substances:

Year:  2014        PMID: 25275022

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116.

Authors:  Daiva Dabkeviciene; Violeta Jonusiene; Vilmante Zitkute; Egle Zalyte; Pranas Grigaitis; Vida Kirveliene; Ausra Sasnauskiene
Journal:  Med Oncol       Date:  2015-10-30       Impact factor: 3.064

2.  Effect of hesperidin on mice bearing Ehrlich solid carcinoma maintained on doxorubicin.

Authors:  Naglaa F Khedr; Rania M Khalil
Journal:  Tumour Biol       Date:  2015-06-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.